Virtus ETF Advisers’s AC Immune ACIU Stock Holding History

Virtus ETF Advisers’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-31,014	Closed	-$124K	–	434
2022 Q1	$124K	Sell	31,014 -1,838	-6%	-$7.96K	0.06%	257
2021 Q4	$163K	Buy	32,852 +4,158	+14%	+$24.2K	0.06%	316
2021 Q3	$193K	Sell	28,694 -1,493	-5%	-$10.7K	0.08%	279
2021 Q2	$239K	Buy	+30,187	New	+$209K	0.1%	223

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Virtus ETF Advisers's ACIU Position: Q2 2022 in Review

Virtus ETF Advisers sold out of AC Immune (ACIU) in Q2 2022, closing a stake of 31,014 shares — an estimated $124K sold.

Virtus ETF Advisers first reported a position in ACIU in Q2 2021 and held it in 4 quarters. The position peaked at $239K in Q2 2021. 35 funds tracked by Wall St. Rank hold ACIU as of Q2 2022.

Virtus ETF Advisers reported no remaining AC Immune position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 31,014 AC Immune shares in Q2 2022, an estimated $124K.
Virtus ETF Advisers first reported a position in AC Immune in Q2 2021 and held it in 4 quarters.
Virtus ETF Advisers's AC Immune position peaked at $239K in Q2 2021.
35 funds tracked by Wall St. Rank held AC Immune as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.